Showing results (71-80 of 814) with videos related to
Sort By:
Pageof 82
Preparative Biochemistry & Biotechnology|August 21, 2023
Synthesis of cellulosic and nano-cellulosic aerogel from lignocellulosic materials for diverse sustainable applications: a reviewAnisha Ganguly, Soma Nag, Kalyan GayenAccounts of Chemical Research|July 25, 2022
Pyrochlores for Advanced Oxygen ElectrocatalysisPralay Gayen, Sulay Saha, Vijay RamaniMolecular Informatics|February 15, 2026
Read-Across Structure-Property Relationship-Based Superior Prediction of Fraction Unbound in Plasma from Chemical Structure: Interpretable Models with Minimum DescriptorsIndrasis Dasgupta, Samima Khatun, Shovanlal GayenJournal of Diabetes and Metabolic Disorders|May 31, 2023
Treatment-duration-wise harm profile of insulin-sodium-glucose co-transporter inhibitor co-treatment in type 1 diabetes mellitus patientsSumanta Saha, Sujata Saha, Mohan GayenSAR and QSAR in Environmental Research|April 16, 2026
Optima: a GUI-based toolkit for developing and validating interpretable machine learning based supervised classification QSAR modelsI Dasgupta, R Roy, S GayenPharmaceutical Research|May 27, 2026
Rational Design, Optimization and Bioinformatic Analysis of Anti-PD-L1 Peptide Conjugated Mocetinostat Prodrug Nanoparticles for Predictive Cancer Chemoimmunotherapeutic EfficacySakuntala Gayen, Ishita Sanyal, Souvik RoyEnvironmental Monitoring and Assessment|May 7, 2020
Avifauna habitability of wetlands in an intensive cultural landscape: insights from the Ichhamati floodplains, IndiaJibananda Gayen, Proshanta Kumar Ghosh, Debajit DattaScientific Reports|August 26, 2022
Catalytic activity and mechanistic investigation of 1D 2-Picolinic acid based Cu(II) coordination polymer in the selective construction of 1,4-disubstituted triazolesMerangmenla Aier, Firdaus Rahaman Gayen, Amrit PuzariJHLT Open|March 27, 2025
Pulmonary hypertension and lung transplantation waitlist outcomes for hypersensitivity pneumonitisMichael J Nicholson, Zehra Dhanani, Shameek GayenHealth Science Reports|January 27, 2025
An Open-Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second-Line Therapy for Advanced Head and Neck Squamous Cell CancersVinod K Ramani, Srimonta Gayen, Radheshyam NaikPageof 82